Live Breaking News & Updates on Bharat Biotech Pvt
Stay updated with breaking news from Bharat biotech pvt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Domestic equity indices advanced for the sixth consecutive day on Wednesday, December 31, 2020. The Sensex at the Bombay Stock Exchange gained 133.14 points, or 0.28 per cent, to close at 47,746.22. The Nifty 50 advanced 49.35 points or 0.35 per cent, to post another record high of 13,981.95. But certain stocks came in news after the market was closed. These stocks can impact the indices when it reopens on Thursday, December 31, 2020. List of such five stocks: Pfizer/AstraZeneca: The Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) that met on Wednesday to consider the Emergency Use Authorisation (EUA) request of Pfizer, Serum Institute of India (SII) and Bharat Biotech Pvt Limited said that the vaccine will not be given authorisation “yet” as more data is needed. Moreover, the SEC will meet again on January 1, 2021, to discuss over approving a COVID-19 vaccine for emergency use in India. ....
Highlights SEC in CDSCO on Wednesday did not grant EUA to COVID-19 vaccine developed by Oxford-AstraZeneca for use in India. The SEC also refused to consider the EUA request of Pfizer and Bharat Biotech Pvt Limited. The SEC is scheduled to meet again on January 1 to hold discussions over this matter. In a significant development, the Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) on Wednesday (December 30) did not grant EUA to COVID-19 vaccine developed by Oxford-AstraZeneca for use in India. The SEC also refused to consider the Emergency Use Authorisation (EUA) request of Pfizer and Bharat Biotech Pvt Limited saying that vaccines developed by all these companies will not be given authorisation “yet” as more data is needed. ....
CDSCO Officials Will Meet On Jan 1 To Discuss Emergency Use Authorization Of COVID Vaccines Dec 31, 2020, 16:24 IST The Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) met on Wednesday to consider the Emergency Use Authorisation (EUA) request of Pfizer, Serum Institute of India (SII) and Bharat Biotech Pvt Limited. According to the statement by the SEC, the Emergency Use was not authorized on Wednesday. They need more data and further time to discuss. The SEC will meet again on January 1. After reviewing further details, they will take a decision about Emergency use of COVID-19 vaccine in India. Pfizer had asked for more time. “Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech Pvt Ltd. was perused and analysed by SEC. ....
No recommendation for emergency approval in India yet, SEC seeks more data from Bharat Biotech, SII India Published: Wednesday, December 30, 2020, 21:49 [IST] New Delhi, Dec 30: The Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) that met on Wednesday did not consider the emergency approval of COVID-19 vaccines from Pfizer, Serum Institute of India (SII) and Bharat Biotech Pvt Limited. According to the report, the SEC said that the vaccine will not be given authorisation yet as more data is needed. Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech Pvt Ltd. was perused and analysed by SEC. The analysis of the additional data and information is going on. SEC will convene again on January 1, the expert panel said in a statement ....